+ Follow PEGYLATED Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1247222
[Title] => Gout patients may need higher allopurinol dose
[Summary] => Most patients with gout need more than the standard and widely used dose of 300 mg/day of allopurinol to lower their serum urate level enough to prevent flares, according to a gout expert.
[DatePublished] => 2013-10-20 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 267041
[Title] => Current status of HCV therapy
[Summary] => Major advances have been made in the treatment of chronic hepatitis C during the last 10 years, but major challenges remain, since treatment with pegylated interferons and ribavirin is effective in only around 55 percent of patients. Newer therapies are needed for the increasing numbers of patients who do not respond to relapse after current treatments with pegylated in interferons and ribavirin.
[DatePublished] => 2004-12-05 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
)
)
PEGYLATED
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1247222
[Title] => Gout patients may need higher allopurinol dose
[Summary] => Most patients with gout need more than the standard and widely used dose of 300 mg/day of allopurinol to lower their serum urate level enough to prevent flares, according to a gout expert.
[DatePublished] => 2013-10-20 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 267041
[Title] => Current status of HCV therapy
[Summary] => Major advances have been made in the treatment of chronic hepatitis C during the last 10 years, but major challenges remain, since treatment with pegylated interferons and ribavirin is effective in only around 55 percent of patients. Newer therapies are needed for the increasing numbers of patients who do not respond to relapse after current treatments with pegylated in interferons and ribavirin.
[DatePublished] => 2004-12-05 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
)
)
abtest
